ESR1 and breast carcinoma: Furthermore, SCCOHT cells have similar or lower half maximal inhibitory concentration (IC50) compared to the control ER+ breast cancer cells MCF7 and CAMA-1 (Fig. 2a, b), the latter among the most palbociclib-sensitive lines in a panel of ~50 breast cancer cell lines32.